Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

This transaction was part of a "Sell to Cover" exercise, automatically implemented to satisfy tax withholding obligations and associated costs. Following this transaction, Mr. Lunger retains ownership ...

In a recent transaction, Norry Elliot, the Chief Medical (TASE:PMCN) Officer of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), executed a sale of 5,584 American Depositary Shares (ADS) on January 17 ...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor ...

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Adaptimmune Therapeutics (ADAP – Research Report), ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Free Report)’s share price crossed below its 50-day moving average during trading on Monday .The stock has a 50-day moving average of $0.62 and ...

We don't wish catastrophic capital loss on anyone. For example, we sympathize with anyone who was caught holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) during the five years that saw its share ...

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade FDA approves Adaptimmune Therapeutics' Tecelra ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Adaptimmune Therapeutics ( (ADAP)) has shared an update. Adaptimmune Therapeutics announced structural changes ...

We don't wish catastrophic capital loss on anyone. For example, we sympathize with anyone who was caught holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) during the five years that saw its share ...

Adaptimmune Therapeutics plc (ADAP) stock price is 0.58 and Adaptimmune Therapeutics plc (ADAP) 10-day simple moving average is 0.58. Adaptimmune Therapeutics plc (ADAP) stock price is 0.58 and ...